Alternatively, you can quite dramatically reduce inflammation in the brain via some simple lifestyle modifications (cutting out sugar, intermittent fasting):<p>Mattson, Mark P., Keelin Moehl, Nathaniel Ghena, Maggie Schmaedick, and Aiwu Cheng. “Intermittent Metabolic Switching, Neuroplasticity and Brain Health.” Nature Reviews. Neuroscience 19, no. 2 (February 2018): 63–80. <a href="https://doi.org/10.1038/nrn.2017.156" rel="nofollow">https://doi.org/10.1038/nrn.2017.156</a>.<p>Pinto, Alessandro, Alessio Bonucci, Elisa Maggi, Mariangela Corsi, and Rita Businaro. “Anti-Oxidant and Anti-Inflammatory Activity of Ketogenic Diet: New Perspectives for Neuroprotection in Alzheimer’s Disease.” Antioxidants 7, no. 5 (April 28, 2018). <a href="https://doi.org/10.3390/antiox7050063" rel="nofollow">https://doi.org/10.3390/antiox7050063</a>.<p>Gao, Yuanqing, Maximilian Bielohuby, Thomas Fleming, Gernot F. Grabner, Ewout Foppen, Wagner Bernhard, Mara Guzmán-Ruiz, et al. “Dietary Sugars, Not Lipids, Drive Hypothalamic Inflammation.” Molecular Metabolism 6, no. 8 (June 20, 2017): 897–908. <a href="https://doi.org/10.1016/j.molmet.2017.06.008" rel="nofollow">https://doi.org/10.1016/j.molmet.2017.06.008</a>.<p>White, Hayden, Karthik Venkatesh, and Bala Venkatesh. “Systematic Review of the Use of Ketones in the Management of Acute and Chronic Neurological Disorders.” Journal of Neurology and Neuroscience 08, no. 02 (2017). <a href="https://doi.org/10.21767/2171-6625.1000188" rel="nofollow">https://doi.org/10.21767/2171-6625.1000188</a>.<p>Alirezaei, Mehrdad, Christopher C. Kemball, Claudia T. Flynn, Malcolm R. Wood, J. Lindsay Whitton, and William B. Kiosses. “Short-Term Fasting Induces Profound Neuronal Autophagy.” Autophagy 6, no. 6 (August 16, 2010): 702–10. <a href="https://doi.org/10.4161/auto.6.6.12376" rel="nofollow">https://doi.org/10.4161/auto.6.6.12376</a>.<p>Mattson, Mark P. “Energy Intake, Meal Frequency, and Health: A Neurobiological Perspective.” Annual Review of Nutrition 25 (2005): 237–60. <a href="https://doi.org/10.1146/annurev.nutr.25.050304.092526" rel="nofollow">https://doi.org/10.1146/annurev.nutr.25.050304.092526</a>.<p>This incidentally also reduces system-wide inflammation among other benefits as well:<p>Houtman, Judith, Kiara Freitag, Niclas Gimber, Jan Schmoranzer, Frank L. Heppner, and Marina Jendrach. “Beclin1‐driven Autophagy Modulates the Inflammatory Response of Microglia via NLRP3.” The EMBO Journal, January 7, 2019, e99430. <a href="https://doi.org/10.15252/embj.201899430" rel="nofollow">https://doi.org/10.15252/embj.201899430</a>.<p>Camell, Christina, Emily Goldberg, and Vishwa Deep Dixit. “Regulation of Nlrp3 Inflammasome by Dietary Metabolites.” Seminars in Immunology 27, no. 5 (September 2015): 334–42. <a href="https://doi.org/10.1016/j.smim.2015.10.004" rel="nofollow">https://doi.org/10.1016/j.smim.2015.10.004</a>.<p>Yamanashi, Takehiko, Masaaki Iwata, Naho Kamiya, Kyohei Tsunetomi, Naofumi Kajitani, Nodoka Wada, Takahiro Iitsuka, et al. “Beta-Hydroxybutyrate, an Endogenic NLRP3 Inflammasome Inhibitor, Attenuates Stress-Induced Behavioral and Inflammatory Responses.” Scientific Reports 7, no. 1 (August 9, 2017): 7677. <a href="https://doi.org/10.1038/s41598-017-08055-1" rel="nofollow">https://doi.org/10.1038/s41598-017-08055-1</a>.<p>Youm, Yun-Hee, Kim Y. Nguyen, Ryan W. Grant, Emily L. Goldberg, Monica Bodogai, Dongin Kim, Dominic D’Agostino, et al. “Ketone Body β-Hydroxybutyrate Blocks the NLRP3 Inflammasome-Mediated Inflammatory Disease.” Nature Medicine 21, no. 3 (March 2015): 263–69. <a href="https://doi.org/10.1038/nm.3804" rel="nofollow">https://doi.org/10.1038/nm.3804</a>.<p>Marín‐Aguilar, Fabiola, Ana V. Lechuga‐Vieco, Elísabet Alcocer‐Gómez, Beatriz Castejón‐Vega, Javier Lucas, Carlos Garrido, Alejandro Peralta‐Garcia, et al. “NLRP3 Inflammasome Suppression Improves Longevity and Prevents Cardiac Aging in Male Mice.” Aging Cell 0, no. 0 (n.d.): e13050. <a href="https://doi.org/10.1111/acel.13050" rel="nofollow">https://doi.org/10.1111/acel.13050</a>.<p>Xiao, Yichen, Wenna Xu, and Wenru Su. “NLRP3 Inflammasome: A Likely Target for the Treatment of Allergic Diseases.” Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 48, no. 9 (2018): 1080–91. <a href="https://doi.org/10.1111/cea.13190" rel="nofollow">https://doi.org/10.1111/cea.13190</a>.<p>Bugyei-Twum, Antoinette, Armin Abadeh, Kerri Thai, Yanling Zhang, Melissa Mitchell, Golam Kabir, and Kim A. Connelly. “Suppression of NLRP3 Inflammasome Activation Ameliorates Chronic Kidney Disease-Induced Cardiac Fibrosis and Diastolic Dysfunction.” Scientific Reports 6 (December 21, 2016). <a href="https://doi.org/10.1038/srep39551" rel="nofollow">https://doi.org/10.1038/srep39551</a>.